Quoin Pharmaceuticals Ltd DRC (QNRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $17.78M
Last updated: Nov 17, 2026 at 4:10 PM ET
Quoin Pharmaceuticals Ltd DRC (QNRX) Statistics
Quoin Pharmaceuticals Ltd DRC (QNRX) has a market cap of $17.78M and an enterprise value of $7.68M. Its share count is up 757.28% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 56.82% below the market cap, as cash exceeds debt.
| Market Cap | $17.78M |
|---|---|
| Enterprise Value | $7.68M |
| Latest price (Nov 17, 2026) | $3.46 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 0.6x |
|---|---|
| P/TBV Ratio | 0.6x |
Price Statistics
The stock is down 76.98% over 52 weeks and trades 28.66% below its 50-day average.
| Beta (1Y) | 0.83 |
|---|---|
| 52-Week Change | -76.98% |
| 1-Month Change | -13.07% |
| 3-Month Change | -26.69% |
| 6-Month Change | -33.08% |
| 5-Year Change | -99.99% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -76.98% |
| Total Return (3Y CAGR) | -71.90% |
| Total Return (5Y CAGR) | -83.32% |
| Return vs SPY (1Y) | -93.58% |
| Max Drawdown (1Y) | -85.43% |
| Max Drawdown (3Y) | -98.28% |
| Sharpe Ratio (1Y) | -1.57 |
| Correlation with SPY (1Y) | 0.10 |
| 50-Day Average | $4.85 |
| 200-Day Average | $5.72 |
| 52-Week Range | $3.25 to $23.50 |
| RSI (14 Days) | 32.5 |
| Average Volume (20 Days) | 11.84K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.20x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.20x |
|---|---|
| Quick Ratio | 7.20x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -68.58% and return on assets is -56.64% over the last 12 months.
| Return on Equity (ROE) | -68.58% |
|---|---|
| Return on Assets (ROA) | -56.64% |
Scores
QNRX has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$20.14M |
| Pretax Income | -$19.68M |
| Net Income | -$19.68M |
| Reported EPS (TTM) | -$6.38 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 82.59% of the $34.75M in total assets.
| Cash and Equivalents | $10.10M |
|---|---|
| Total Debt | $0 |
| Net Cash | $10.10M |
| Working Capital | $29.62M |
| Shareholder Equity | $28.70M |
| Tangible Book Value | $28.39M |
| Total Assets | $34.75M |
| Total Liabilities | $6.05M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $7 of capital spending, operating cash flow left -$18.93M of free cash flow.
| Operating Cash Flow | -$18.93M |
|---|---|
| Capital Expenditures | $7 |
| Free Cash Flow | -$18.93M |
| FCF Per Share | -$3.94 |
| Depreciation and Amortization | $100.43K |
Trailing 12 months through Sep 30, 2026.
Stock Splits
The last split was a 1-for-35 reverse split on Apr 9, 2025.
| Last Split Date | Apr 9, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:35 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About QNRX
What is QNRX's market cap?
Quoin Pharmaceuticals Ltd DRC has a market cap of $17.78M. Its enterprise value, which adds debt and subtracts cash, is $7.68M.
How many shares of QNRX are outstanding?
Quoin Pharmaceuticals Ltd DRC has 5.04M shares outstanding. The count is up 757.28% from a year earlier.
Does QNRX pay a dividend?
No. Quoin Pharmaceuticals Ltd DRC does not pay a dividend.
How much debt does QNRX have?
Quoin Pharmaceuticals Ltd DRC has $0 of total debt and $10.10M of cash and equivalents, a net cash position of $10.10M.
QNRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors